2024 ASCO® Annual Meeting
1 May-31 Jul 2024 | Wed, 05/01/2024 - 01:00 Wed, 07/31/2024 - 01:00
Connect with Labcorp at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting
May 31 – June 24, 2024 | Chicago, IL | Booth 33093
ONE partner to address your precision medicine needs.
As your partner in cancer care, we deliver a comprehensive breadth of services and key insights to help you make the right healthcare decisions at the right time for your patients. From risk assessment and diagnosis to treatment selection and monitoring, our expertise, efficient turnaround times and streamlined reporting can help you keep pace with evolving biomarkers, and make quick decisions that improve outcomes.
Join us at booth 33093 to discover our extensive portfolio.
- Labcorp signature testing panels
- Labcorp® Plasma Focus™: A guideline driven liquid biopsy test
- Omniseq® INSIGHT: Comprehensive solid tumor NGS assay for DNA and RNA
- PGDx elio™ tissue complete: FDA cleared kitted solution for pan solid tumor CGP
- IntelliGEN® Myeloid: NGS assay for myeloid malignancies
- VistaSeq®: A portfolio of multi-gene tests for hereditary cancers
- Labcorp® Plasma Detect™: A tumor-informed whole-genome ctDNA MRD assay: accelerate oncology therapeutic development with fast, high-confidence MRD assessment for global clinical trials
- Clinical development and commercialization: Biomarker discovery and strategy development, companion diagnostic development, sponsored testing and NGS kitted solutions
- Testing solutions: Streamlined CGP solutions; centralized services for hereditary, tissue, liquid and heme testing; translational research opportunities for kitted solutions and centralized services
Poster presentations:
| Session Date & Time | Presenting Author | Title | Details |
| Saturday, June 1 | |||
| Saturday, June 1 9:00AM–12:00PM | Kyle Strickland | A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability | Poster Session: Care Delivery/Models of Care Abstract #1554 |
| Saturday, June 1 9:00AM–12:00PM | Ellen Verner | Analytical Validation of the Labcorp® Plasma Complete™ Test to Enable Precision Oncology Through Solid Tumor Liquid Biopsy Comprehensive Genomic Profiling | Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Abstract #3063 |
| Saturday, June 1 9:00AM–12:00PM | Yu Fujiwara (UCSD) | Pan-cancer B- and T-cell transcriptome analysis reveals CXCL13 as a predictive marker for immune checkpoint inhibitor response | Poster Session: Developmental Therapeutics—Immunotherapy Abstract #2626 |
| Saturday, June 1 9:00AM–12:00PM | Hirotaka Miyashita (UCSD) | CRTAM is an independent predictive biomarker for immune checkpoint blockade in a pan-cancer cohort | Poster Session: Developmental Therapeutics—Immunotherapy Abstract #2630 |
| Saturday, June 1 9:00AM–12:00PM | Brigid Larkin (UCSD) | Diversity in B7-H3/CD276 expression across cancer types: exploring a dynamic novel immune checkpoint. | Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Abstract #3133 |
| Session Date & Time | Presenting Author | Title | Details |
| Sunday, June 2 | |||
| Sunday, June 2 9:00AM–12:00PM | Heidi Ko | Novel HLA-Ilo/HLA-IIhi phenotype suggests pattern of immune evasion in triple-negative breast cancer | Poster Session: Breast Cancer—Metastatic Abstract #1095 |
| Sunday, June 2 9:00AM–12:00PM | RJ Seager | Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer suggests a mechanism of immune evasion and tumor progression | Poster Session: Breast Cancer—Metastatic Abstract #1096 |
| Session Date & Time | Presenting Author | Title | Details |
| Online | |||
| e15148 | Michelle Green | Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers | Online Only |
| e15166 | Mary Nesline | Multi-specimen Comprehensive Genomic Profiling for Diagnostic Disambiguation in Advanced and Metastatic Solid Tumors | Online Only |
| e13545 | Mary Nesline | Screening for Social Determinants of Health Among Advanced and Metastatic Cancer Patients Undergoing Comprehensive Genomic Profiling in Underserved Communities | Online Only |
| e14654 | Sabi Pabla | Pervasive loss of antigen presentation in solid tumors driven by loss of HLA class I expression | Online Only |
| e21544 | Mariafern Senosainortega | Comprehensive genomic and immune profiling reveals distinct molecular features of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK Inhibitors | Online Only |
| e13035 | Zach Wallen | Sequential biopsies of real-world primary and metastatic breast cancer have tissue-dependent reductions in tumor inflammation and PD-L1 expression | Online Only |